Biotech Values

[DewDiligence]

ABBV/ENTA—Your line of thinking would make more sense if we were taking about long-term therapy, but the V-Pak regimen is only 12 weeks. It’s highly unlikely (IMO) that V-Pak can cause material liver damage in 12 weeks to patients whose only pre-treatment etiology is non-cirrhotic HCV.

In the phase-3 clinical trials, V-Pak was tested on about 2,000 non-cirrhotic patients. There were no drug-related deaths and the discontinuation rate from adverse events was less than 1%.